檢索結果 - Hasmann, Max

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab 由 Mamidi, Srinivas, Cinci, Marc, Hasmann, Max, Fehring, Volker, Kirschfink, Michael

獲取全文 獲取全文 獲取全文

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab 由 Hughes, Juliana Bentes, Rødland, Marianne Skeie, Hasmann, Max, Madshus, Inger Helene, Stang, Espen

獲取全文 獲取全文 獲取全文

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer 由 Collins, Denis, Jacob, Wolfgang, Cejalvo, Juan Miguel, Ceppi, Maurizio, James, Ian, Hasmann, Max, Crown, John, Cervantes, Andrés, Weisser, Martin, Bossenmaier, Birgit

獲取全文 獲取全文 獲取全文

Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis 由 Kemmer, Svenja, Berdiel-Acer, Mireia, Reinz, Eileen, Sonntag, Johanna, Tarade, Nooraldeen, Bernhardt, Stephan, Fehling-Kaschek, Mirjam, Hasmann, Max, Korf, Ulrike, Wiemann, Stefan, Timmer, Jens

獲取全文 獲取全文 獲取全文

Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions 由 Schmid, Ingrid, Bonnington, Lea, Gerl, Monika, Bomans, Katrin, Thaller, Anna Louisa, Wagner, Katharina, Schlothauer, Tilman, Falkenstein, Roberto, Zimmermann, Boris, Kopitz, Jürgen, Hasmann, Max, Bauss, Frieder, Haberger, Markus, Reusch, Dietmar, Bulau, Patrick

獲取全文 獲取全文 獲取全文

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts 由 Berdiel-Acer, Mireia, Maia, Ana, Hristova, Zhivka, Borgoni, Simone, Vetter, Martina, Burmester, Sara, Becki, Corinna, Michels, Birgitta, Abnaof, Khalid, Binenbaum, Ilona, Bethmann, Daniel, Chatziioannou, Aristotelis, Hasmann, Max, Thomssen, Christoph, Espinet, Elisa, Wiemann, Stefan

獲取全文 獲取全文 獲取全文

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small... 由 Cejalvo, Juan-Miguel, Jacob, Wolfgang, Fleitas Kanonnikoff, Tania, Felip, Enriqueta, Navarro Mendivil, Alejandro, Martinez Garcia, Maria, Taus Garcia, Alvaro, Leighl, Natasha, Lassen, Ulrik, Mau-Soerensen, Morten, Adessi, Celine, Michielin, Francesca, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés

獲取全文 獲取全文 獲取全文

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-... 由 Schneeweiss, Andreas, Park-Simon, Tjoung-Won, Albanell, Joan, Lassen, Ulrik, Cortés, Javier, Dieras, Veronique, May, Marcus, Schindler, Christoph, Marmé, Frederik, Cejalvo, Juan Miguel, Martinez-Garcia, Maria, Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Céline, Moisan, Annie, Meneses-Lorente, Georgina, Racek, Tomas, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés

獲取全文 獲取全文 獲取全文

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer 由 Collins, Denis M., Madden, Stephen F., Gaynor, Nicola, AlSultan, Dalal, Le Gal, Marion, Eustace, Alex J., Gately, Kathy A., Hughes, Clare, Davies, Anthony M., Mahgoub, Thamir, Ballot, Jo, Toomey, Sinead, O’Connor, Darran P., Gallagher, William M., Holmes, Frankie A., Espina, Virginia, Liotta, Lance, Hennessy, Bryan T., O’Byrne, Kenneth J., Hasmann, Max, Bossenmaier, Birgit, O’Donovan, Norma, Crown, John

獲取全文 獲取全文 獲取全文